Mobile

An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participa...

Update Il y a 4 ans
Reference: EUCTR2008-002022-10

An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participated in previous Roche or Roche partner protocols. Protocollo in aperto, multicentrico, sulla somministrazione di interferone pegilato alfa-2a (PEGASYS) in monoterapia o in combinazione a ribavirina (COPEGUS) in pazienti affetti da epatite cronica C che hanno partecipato a precedenti protocolli di Roche o di un partner di Roche

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To provide treatment or re-treatment with PEGASYS as monotherapy or in combination with COPEGUS, to patients with CHC who participated in a previous Roche or Roche partner protocol where access to treatment or re-treatment was promised or deemed appropriate following completion of the original protocol (‘donor' protocol). Fornire il trattamento o ritrattamento con PEGASYS in monoterapia o in combinazione a COPEGUS ai pazienti affetti da CHC che hanno partecipato ad un precedente protocollo di Roche o di partner Roche, dove il trattamento o il ritrattamento con PEGASYS in monoterapia o in combinazione e' stato promesso o ritenuto appropriato dopo completamento del protocollo di provenienza (protocollo 'donatore')

Inclusion criteria

  • Chronic Hepatitis C(CHC),Epatite cronica C (CHC)

Links